Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review

Abstract

Background and Objective: The adoption of targeted therapy and immunotherapy has revolutionised the treatment landscape of non-small cell lung cancer. For early staged disease, incorporation of targeted therapy and immunotherapy has recently been demonstrated to reduce recurrence. Development of targeted therapies in advanced lung cancer is driven by advanced genomic sequencing techniques, better understanding of drug resistance mechanisms, and improved drug designs. The list of targetable molecular alteration is continuously expanding, and next generation molecular therapies have shown promise in circumventing drug resistance. Lung cancer patients may achieve durable disease control with immune checkpoint inhibitors however most patients develop immunotherapy resistance. A wide spectrum of resistance mechanisms, ranging from impaired T-cell activation, presence of coinhibitory immune checkpoints, to immunosuppressive tumour microenvironment, have been proposed. A multitude of novel immunotherapy strategies are under development to target such resistance mechanisms. This review aims to provide a succinct overview in the latest development in targeted therapy and immunotherapy for NSCLC management. Methods:We searched all original papers and reviews on targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC) using PubMed in June 2022. Search terms included "non-small cell lung cancer", "targeted

Enhanced CT-based radiomics model to predict natural killer cell infiltration and clinical prognosis in non-small cell lung cancer

“…Several challenges remain in the contemporary field of NSCLC management. Despite the increased adoption of molecular targeted therapies and immunotherapies, a subset of patients, especially those with advanced disease stages, exhibit limited therapeutic responses (19). Despite their potential, the emergence of innovative diagnostic modalities faces barriers, such as high costs and intricate technical demands that limit their widespread adoption (20).…”

Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib

“…The management of advanced lung cancer has evolved into the era of precision medicine ( 26 , 27 ). The selection of an appropriate treatment regimen is determined not merely by the histological subtype but also by the presence of specific driver mutations and the level of PD-L1 expression ( 28 , 29 ).…”

Anticancer activities of natural antimicrobial peptides from animals

“…Chemotherapeutics (i.e., alkylating agents, antimetabolic agents, antineoplastic antibiotics, platinating agents, and plant-derived alkaloids) exert anti-tumor effects through direct cytotoxic effects or indirectly by affecting the cell cycle ( Okunaka et al, 2021 ). Progress in molecular targeted drugs has prolonged survival ( Li et al, 2023 ), particularly in patients with lung cancer harboring epidermal growth factor receptor (EGFR) mutations (i.e., erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib) or anaplastic lymphoma kinase (ALK) rearrangement (i.e., ceritinib, alectinib, brigatinib, ensartinib, lorlatinib), and in patients with breast cancer harboring human epidermal growth factor receptor 2 (HER2) amplification (i.e., trastuzumab). Furthermore, cancer immunotherapies targeting the interaction of programmed cell death 1 (PD-1) with its major ligands, PD-L1 and PD-L2 are considered to usher in the era of modern oncology.…”